New Delhi, May 17, 2020: Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house…
Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…